{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:25:03Z","timestamp":1793413503942,"version":"4.5.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Secondary antibody deficiencies (SADs) are a significant but frequently under-recognised group of acquired immunodeficiencies. They may arise in various clinical settings, including haematological malignancies, immunosuppressive therapies, and protein-losing conditions. SADs are associated with an increased risk of recurrent and severe infections, hospitalisation, and impaired quality of life. Despite this, diagnostic and treatment pathways remain inconsistent across healthcare settings and regions. Recent advances in the use of structured clinical data, including electronic health records and systematic laboratory assessments, show promise in facilitating earlier recognition of SADs. These approaches support more timely treatment decisions and promote consistent standards of care. Achieving improved outcomes for individuals with SADs will require broader consensus on diagnostic criteria, treatment thresholds, and access to specialist immunology services.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1635094","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:35:02Z","timestamp":1759815302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Secondary antibody deficiencies in the modern era: emerging trends, diagnostic pitfalls, and advances in personalised management"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuayb","family":"Elkhalifa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haggar","family":"Elbashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saed","family":"Isse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuzakouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Medhat Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Bhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.102117","article-title":"Management of secondary immunodeficiency in patients with B-cell haematological Malignancies: diagnosis, vaccination and immunoglobulin replacement","volume":"107","author":"Shah","year":"2023","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.413","article-title":"Secondary immunodeficiencies: an overview","volume":"127","author":"Tuano","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.240063","article-title":"Overview of secondary immunodeficiency","volume":"45","author":"Herman","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological Malignancy: European expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur J Haematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cei\/uxac070","article-title":"British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UK-PIN) consensus guideline for the management of immunoglobulin replacement therapy","volume":"210","author":"Grigoriadou","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/10428194.2021.1992761","article-title":"Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with haematological Malignancies","volume":"63","author":"Jolles","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","first-page":"AB215","DOI":"10.1016\/j.jaci.2019.12.251","article-title":"Secondary immunodeficiency: a difficult diagnosis","volume":"145","author":"Manh\u00e3es","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7365\/JHPOR.2019.1.1","article-title":"Secondary immunodeficiencies \u2013 do we need systemic solutions","volume":"1","author":"Jahnz-R\u00f3\u017cyk","year":"2019","journal-title":"J Health Policy Outcomes Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.024","article-title":"If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"13","author":"Otani","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.iac.2018.08.005","article-title":"Secondary hypogammaglobulinemia: an increasingly recognized complication of treatment with immunomodulators and after solid organ transplantation","volume":"39","author":"Kaplan","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"B15","doi-asserted-by":"publisher","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J Neuroimmunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study","volume":"62","author":"Podest\u00e0","year":"2023","journal-title":"J Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.v71.11","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.815710","article-title":"Good's syndrome: time to move on from reviewing the past","volume":"12","author":"Kabir","year":"2022","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106100","article-title":"How to investigate a suspected immune deficiency in adults","volume":"171","author":"Grammatikos","year":"2020","journal-title":"Respir Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100324","article-title":"Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement","volume":"9","author":"Duraisingham","year":"2014","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928062","article-title":"Secondary immune deficiency and primary immune deficiency crossovers: hematological Malignancies and autoimmune diseases","volume":"13","author":"Ballow","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00586","article-title":"Primary and secondary immunodeficiency diseases in oncohaematology: warning signs, diagnosis, and management","volume":"10","author":"S\u00e1nchez-Ram\u00f3n","year":"2019","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological Malignancy-associated secondary immunodeficiency","volume":"101","author":"Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107365","article-title":"Management of humoral secondary immunodeficiency in hematological Malignancies and following hematopoietic stem cell transplantation: Regional perspectives","volume":"133","author":"Ar","year":"2023","journal-title":"Leuk Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10875-024-01818-2","article-title":"Dissecting secondary immunodeficiency: identification of primary immunodeficiency within B-cell lymphoproliferative disorders","volume":"45","author":"Palacios-Ortega","year":"2024","journal-title":"J Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011231","article-title":"Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological Malignancy","volume":"8","author":"McQuilten","year":"2024","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000691","article-title":"Artificial intelligence and the hunt for immunological disorders","volume":"20","author":"Rider","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0469-4","article-title":"Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and republic of Ireland","volume":"38","author":"Edgar","year":"2018","journal-title":"J Clin Immunol"},{"key":"B30","volume-title":"NCCP Guidance Document 0017 \u2013 Patient selection for the use of immunoglobulin replacement therapy in cancer patients with secondary immunodeficiency","year":"2026"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196356","article-title":"Current approach in the management of secondary immunodeficiency in patients with hematological Malignancies: spanish expert consensus recommendations","volume":"12","author":"Boqu\u00e9","year":"2023","journal-title":"J Clin Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/frhem.2024.1347708","article-title":"Management of secondary immunodeficiency in hematological Malignancies: a Delphi consensus from the Middle East","volume":"3","author":"Dimou","year":"2024","journal-title":"Front Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023935","article-title":"A clinician survey for management of the secondary immunodeficiency caused by haematological Malignancies in China","volume":"100","author":"Ye","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in haematological Malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2176843","article-title":"Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review","volume":"16","author":"Cinetto","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2025.104875","article-title":"Rapid review: Growing usage of Multimodal Large Language Models in healthcare","volume":"1","author":"Gupta","year":"2025","journal-title":"J BioMed Inform"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1109\/MPRV.2024.3499513","article-title":"Multimodal large language models in human-centered health: practical insights","volume":"23","author":"Dang","year":"2024","journal-title":"IEEE Pervasive Computing"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00412-8","article-title":"Large-scale deep learning analysis to identify adult patients at risk for combined and common variable immunodeficiencies","volume":"3","author":"Papanastasiou","year":"2023","journal-title":"Commun Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4510","article-title":"Electronic health record signatures identify undiagnosed patients with common variable immunodeficiency disease","volume":"16","author":"Johnson","year":"2024","journal-title":"Sci Trans Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1145\/363748","article-title":"Explainable AI for medical data: current methods, limitations, and future directions","volume":"57","author":"Hossain","year":"2023","journal-title":"ACM Computing Surveys"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imed.2025.01.001","article-title":"Large language models-powered clinical decision support: enhancing or replacing human expertise","volume":"5","author":"Li","year":"2025","journal-title":"Intelligent Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.668045","article-title":"Multi-omics approaches in immunological research","volume":"12","author":"Chu","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1635094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:35:03Z","timestamp":1759815303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1635094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2025.1635094"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1635094","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"article-number":"1635094"}}